The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARγ ligands

This publication has 78 references indexed in Scilit:

• Effects of Hyperglycemia and Hyperinsulinemia on Circulating Tissue Factor Procoagulant Activity and Platelet CD40 Ligand
  Diabetes, 2006
• Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARβ
  The FASEB Journal, 2005
• Induction of PPARβ and prostacyclin (PGI₂) synthesis by Raf signaling: failure of PGI₂ to activate PPARβ
  The FEBS Journal, 2005
• Tesaglitazar, a dual PPARα/γ agonist, ameliorates glucose and lipid intolerance in obese Zucker rats
  American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2005
• Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products
  Diabetes and Vascular Disease Research, 2005
• Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
  American Heart Journal, 2004
• Novel prostaglandin D2-derived activators of peroxisome proliferator-activated receptor-γ are formed in macrophage cell cultures
  Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2003
• Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT₁ receptor antagonist losartan
  British Journal of Pharmacology, 2001
• Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel
  New England Journal of Medicine, 2000
• Bioactivation of xenobiotics by prostaglandin H synthase
  Chemico-Biological Interactions, 1991